Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders

Part of paid clinical trials in Albuquerque, New Mexico.

Sponsor
Spanish Foundation for Neurometrics Development
Study ID
NCT06368726
Phase
PHASE1
Status
Enrolling By Invitation

Conditions

  • Attention
  • EEG With Periodic Abnormalities
  • Fluency Disorder
  • Social Behavior
  • Visual Perceptual Weakness

Eligibility Criteria

Sex
ALL
Age
6 Years - 11 Years
Healthy Volunteers
Not accepted

Interventions

  • tDCS or Transcranial Direct Current Stimulation — DEVICE
    We use weak currents applied over the child's scalp over 30 minutes twice a week during 100 days
  • Risperidone — DRUG
    Risperidone Risperidone according to child's weighs

Study Details

Results of the application of 100 sessions of tDCS for 12 months in children between 6 and 11 years old with autism spectrum disorder with rare diseases, genetic problems or PANDAS

Key Dates

Start date
Apr 1, 2024
Status verified
May 2026
Primary completion
Dec 12, 2025
Completion
Jun 2, 2026

Study Design

Enrollment
180 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Traditional ASD approach
    The childs receive their tradicional interventions, Risperidone according to child's weight, diet, educational or speech therapies, pictographs.
  • Experimental: This group of childs will receive tDCS sessions
    This children receive 100 sessions during 12 monts in 4 groups of 25 sessions 2 per week of 30 minutes with a separation between them of at least 72 hours

Primary Outcome Measure

FFT [ Time Frame: 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Bigdata4brain LLCAlbuquerqueNew Mexico87113-

Find similar trials in Albuquerque, NM

By research site
Bigdata4brain LLC· Albuquerque, NM

Related Studies